Project Grant HT94252410167
Award Date
4/15/24
Completion Date
4/14/26
Dollars Obligated
$854K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Topsfield, MA 01983, USA
Similar Awards
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
This $925,757 Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports research conducted by Wake Forest University Health Sciences (WFUHS) to selectively reduce repeat expansion RNA with small molecules to treat C9ORF72 mediated Amyotrophic Lateral Sclerosis (ALS). The award period is from April 1, 2025 to March 31, 2027. The Military Medical Research and Development program funds a wide range of...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This federal Project Grant award, valued at $1,078,882.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research project conducted by the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, CA. The project aims to investigate a "chemical engineering approach to ALS that amplifies a more sophisticated view of the multimodal therapeutic actions of donor and host neural stem cells in that...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Van Andel Research Institute was awarded a $950,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 30, 2023 to September 29, 2025 to establish the neuroprotective potential of C9ORF72 hypermethylation in repeat expansion-caused ALS. Through this award, the grantee will investigate medical solutions for the battlefield by transforming health care for service members and the...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This $1,995,027 federal Project Grant award to the University of California, San Diego (UCSD) was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant funds a 3-year research project to develop engineered RNA-targeting zinc finger proteins for the treatment of C9ALS, a rare genetic form of amyotrophic lateral sclerosis. The research aims to advance therapeutic approaches for this debilitating neurological disorder, with a...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $300,387.00 to Twilight Bioscience, Inc. for the period of February 1, 2025 to January 31, 2027. The grant funds an "Integrated Precision Immunology Approach for Developing an Fc-Fusion Vaccine to Treat Frontotemporal Dementia". This research aims to develop an innovative vaccine to address frontotemporal dementia, a...
The University of California, San Diego received a $694,650 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award will support research on RNA-directed therapy for amyotrophic lateral sclerosis (ALS) linked to the C9ORF72 gene using engineered zinc finger nucleases. The Military Medical Research and Development program aims to transform military and public health through...